FDA Rejects Proposed Xarelto Antidote

Written By:
Jessie Paluch
Jessie Paluch

Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.

This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.

TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.

FDA Rejects Proposed Xarelto Antidote

Portola Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) failed to approve AndexXa, the Xarelto antidote currently in development for uncontrollable bleeds.

Currently, there is no reversal agent for uncontrolled bleeding associated with the anticoagulants Xarelto or Eliquis which have been linked to fatal brain and stomach bleeds.

Xarelto lawsuits continue to be filed.

Xarelto antidote rejected by fda
Table of Contents

Xarelto Antidote

The application for the Xarelto Antidote, AndexXa was based on data from the two-phase III ANNEXA-A and ANNEXA-R trials.

Those studies, published in the New England Journal of Medicine, showed that AnderXa effectively reversed the anticoagulant activity of Eliquis and Xarelto in healthy volunteers with no serious adverse events.

Although the FDA granted AndexXa expedited review, the agency decided that it needs more information before the drug can be approved.

The FDA requested additional information describing the drug’s manufacturing process and said it needed to review changes Portola has made to its post-marketing commitments.

According to a statement released by the company, it plans to resubmit its application before the end of 2016.

Why Do Doctors Prescribe Xarelto And Without A Known Xarelto Antidote?

Blood thinners like Xarelto and Eliquis are used to prevent strokes and blood clots following surgery for people with atrial fibrillation.

Unlike warfarin, which has been used for decades, the non-vitamin K antagonist oral anticoagulants (NOACs) Xarelto, Eliquis, and Pradaxa do not require frequent blood tests or dietary restrictions.

The only other approved reversal agent for the NOACs, given by the FDA in October 2015, is Praxbind, an antidote for Pradaxa.

Given the fact that there is no Xarelto antidote, many physicians are wary of prescribing the new anticoagulants, since there is limited evidence on how to manage bleeding in patients taking Xarelto and there is no known reversal of the anticoagulant effect.

According to the Institute of Safe Medicines Practices (ISMP), a watchdog group, anticoagulant drugs are a “high-risk treatment” and cause bleeding in approximately 15% of patients with atrial fibrillation.

The lack of a specific antidote was one factor that led to over 4,000 lawsuits being filed against Boehringer Ingelheim, the maker of Pradaxa who recently agreed to pay $650 million to settle these lawsuits.

Xarelto is now the top prescribed anticoagulant in the U.S

Xarelto Lawsuits Move Forward

As the number of adverse events linked with these blood thinners rise, so do the lawsuits.

More than 7,200 federal lawsuits against the manufacturer of Eliquis are currently pending and have been consolidated into multidistrict litigation (MDL) 2592 in the District of Louisiana, and a mass tort program in the state of Pennsylvania, where more than 800 have been centralized.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources